Welcome to Justin Stindt Consultants – your dedicated market access consulting partner for successful fundraising and investor engagement for healthcare ventures. As a leading market access consultancy for the pharmaceutical , biotech , and medtech industries, we excel in bridging the gap between groundbreaking science and the capital investment needed to bring it to market. Our goal is to ensure your venture not only gains access to crucial funding but does so in a way that maximizes your company’s value and long-term success. Leverage our global network of industry investors, strategic partners, and specialized consultants to navigate the competitive landscape of life science funding. Our firm provides full-service support in developing and executing fundraising strategies and investor engagement plans, including identifying the right investors, crafting compelling pitch decks and business plans, and applying our experience from numerous successful projects to ensure your story resonates and secures the funding it deserves.
Fundraising & Investor Engagement in Life Sciences: At a Glance
Securing capital for Pharma, Biotech, and Medtech innovation requires more than clinical data; it demands a narrative that bridges scientific excellence with Market Access and commercial viability. Justin Stindt Consultants empowers healthcare innovators to navigate the funding landscape, from Seed to Series C, by aligning their value proposition with specific investor priorities.
- Strategic Investor Mapping: Identifying VCs, corporate partners, and angel networks aligned with your development stage.
- Tailored Pitch Development: Customizing messaging for financial VCs (ROI-focused) versus corporate investors (portfolio fit and clinical synergy).
- Market Access Integration: Quantifying the impact of reimbursement and regulatory milestones on your company’s valuation.
The JSC Edge: We translate complex clinical milestones into actionable business cases that resonate with global healthcare investors.
DEVELOPING EFFECTIVE FUNDRAISING STRATEGIES FOR PHARMA, BIOTECH, MEDTECH, AND DIGITAL HEALTH INNOVATORS
Securing sufficient funding is often as critical to a new therapy or medical technology as its clinical efficacy. To drive sustainable growth, it is essential to have a robust fundraising strategy that aligns with investor expectations and clearly communicates the value and potential of your product.
An understanding of the commercial opportunity, competitive landscape , and even reimbursement outlook is crucial in shaping a narrative that instils confidence in investors. Different types of investors will focus on different aspects, some prioritize market size and revenue potential, while others emphasize innovative science or strategic fit and addressing these points in a targeted way is key.
At Justin Stindt Consultants, we have experience guiding numerous life science companies through successful fundraising campaigns and investor engagements, and we strongly believe our team of experts can help you achieve the best possible outcome in securing the capital your venture needs.
TAILORED INVESTOR ENGAGEMENT STRATEGIES BASED ON UNDERSTANDING INVESTOR PRIORITIES AND MARKET POTENTIAL
In our consultancy’s experience, it is essential to understand the investor’s perspective and criteria in order to develop a successful fundraising strategy. Once our market access consultants have gained an in-depth understanding of your value proposition and the market potential of your innovation, our firm employs state-of-the-art approaches to engage investors effectively.
While we cannot reveal all of our trade secrets here, we often conduct thorough investor mapping to identify those venture capital firms, angel networks, or strategic corporate investors most aligned with your field. We help customize your pitch to address what matters most to each target investor, whether it’s robust clinical data, a clear path to market access, or a strong exit strategy.
Unlike one-size-fits-all advisories, our agency carefully adapts the fundraising approach to your specific product, development stage, and audience. The strategy and messaging will differ for a pre-clinical biotech seeking seed funding versus a medtech company with early revenues preparing for a Series B round. For instance, a financial VC may be most interested in market size and projected ROI, whereas a pharmaceutical corporate investor might focus on how your solution complements their portfolio and the evidence of clinical and payer acceptance. We design our engagement plans to speak the language of each investor type, ensuring that every discussion highlights the aspects of your venture that each stakeholder values most.
FUNDRAISING & INVESTOR ENGAGEMENT - What Sets Justin Stindt Consultants Apart?
Put simply, our consulting company helps clients determine what key factors and milestones they need to address to attract investment and strategic partnerships. Our team conducts thorough primary and secondary research to assess the investment landscape, benchmark comparable ventures, and identify the value proposition levers that will maximize investor interest in your company. Our network spans across the healthcare industry and investment community, including venture capitalists, industry executives, and scientific Key Opinion Leaders, allowing us to gather insider perspectives and even facilitate introductions to potential investors or partners when appropriate.
We deliver specific and actionable insights on investor-resonating metrics and milestones, helping you translate complex clinical and market data into a compelling business case. This can include articulating your health outcomes and market access plan in terms of commercial value, or quantifying the upside of key development milestones. For example, we often evaluate how achieving an additional clinical endpoint or securing early reimbursement in a major market could impact your product’s revenue projections, giving investors a clear view of the upside potential.
Our holistic approach integrates deep understanding of healthcare systems, regulatory and reimbursement processes, strategic vision, and investor expectations to provide solutions that truly create value and credibility. We tailor every fundraising or investor engagement project to the exact needs of our clients and maintain close collaboration throughout the process, ensuring our experts and partners co-develop the best possible strategy to secure funding for your business.
We work with clients of all sizes, from lean start-ups to established pharmaceutical companies, and offer fundraising support at all stages of the business lifecycle. For example, we assist biotech entrepreneurs preparing for seed or Series A rounds, medtech scale-ups seeking Series B or C growth capital, and even large healthcare companies exploring spin-out financing or strategic partnerships. We also support investors, such as venture funds or corporate business development teams, by providing due diligence insights on market potential and market access viability of potential targets. Our agency is dedicated to ensuring your company navigates the fundraising process efficiently and successfully, connecting innovation with the capital it needs to thrive.
Resources for Early-Stage Companies
If you are an early-stage company, you may find the links below useful to get you started. For further insights and in later stages, we recommend contacting us directly for the most accurate and tailored support.
EU
EIT Health – European health innovation accelerator connecting biotech and medtech startups with investors, funding programmes, and industry partners across Europe.
European Commission Research & Innovation Funding – Official EC portal listing open calls, grants, and funding opportunities for healthcare research and innovation projects across Europe.
EXIST Business Start-up Grant – German federal programme offering startup grants and entrepreneurship coaching for science- and technology-based early-stage companies, including healthcare and biotech ventures.
https://www.bpifrance.fr/sante
Bpifrance Santé – France’s public investment bank for the health sector, providing grants, loans, and equity financing for biotech, medtech, and digital health startups and scale-ups.
High-Tech Gründerfonds (HTGF) – Germany’s leading seed-stage venture capital investor for deep tech and life sciences startups, offering early-stage funding and strategic support to innovative companies.
https://www.eif.org/press/all/eif-german-equity-boost-for-innovation-and-startups
EIF German Equity Boost – European Investment Fund initiative providing equity financing and co-investment opportunities to support innovation and startup growth across Germany.
US
SBIR (Small Business Innovation Research) – US federal programme offering competitive non-dilutive grants to small businesses for R&D across healthcare, biotech, and technology sectors.
https://seed.nih.gov/small-business-funding/find-funding
NIH Seed Fund – National Institutes of Health funding finder to identify SBIR and STTR grant opportunities for small businesses engaged in healthcare and biomedical research commercialisation.
NSF America’s Seed Fund – National Science Foundation programme providing SBIR and STTR grants to early-stage deeptech and life sciences startups to accelerate R&D and commercialisation.
https://simpler.grants.gov/search
Grants.gov Search – Official US federal grants database to search and apply for government funding across health, research, and technology programmes from all federal agencies.
Meet one of our Fundraising & Investor Engagement experts
Get in touch with our expert
CLIENT TESTIMONIALS
